A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Singh, Harcharan
- Comparative Study to Evaluate Efficacy & Cost Effectiveness of Olmesartan Versus Telmisartan, in Patients of Stage I Hypertension
Authors
1 Department of Pharmacology, Government Medical College, Patiala, Punjab, IN
2 Department of Cardiology, Government Medical College, Patiala, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 4, No 1 (2015), Pagination: 568-576Abstract
Background: Hypertension is one of the most common diseases in the world. It is an important and independent risk factor for atherosclerosis, heart failure, renal disease, and peripheral arterial disease. It is directly responsible for 57% of all stroke deaths and 42% of coronary heart disease deaths in India.
Objectives: To evaluate and compare efficacy and cost effectiveness in hypertensive patients receiving Olmesartan and Telmisartan in Stage I hypertension.
Material and methods: The present study was an open, prospective, randomized, parallel group comparative study conducted in 60 patients of stage I hypertension over a period of 16 weeks. Patients were randomly allocated to two, age and sex, matched groups of 30 patients each. Group I patients were started on Olmesartan at a dose of 20 mg&Group II patients were put on Telmisartan at a dose of 40 mg. The BP lowering efficacy and cost effective analysis of Olmesartan versus Telmisartan was calculated&compared. The data was entered in Microsoft excel and compiled. Statistical analysis was done using various tests.
Results: Maximum patients in both the groups were in age group of 51-60 years. In group I there were 13 males and 17 females. In group II there were 14 males and 16 females. Both Olmesartan and Telmisartan are effective in lowering systolic&diastolic BP in supine&sitting positions&mean BP is also lowerer, more in Olmesartan group. By cost effective analysis Telmisartan was found more cost effective. Incremental cost effective ratio was found to be 218.35.
Conclusion: Both Olmesartan and Telmisartan belong to the same antihypertensive drug class, effectively reduce systolic and diastolic blood pressure at various visits. Taking into account Total cost Telmisartan was more cost effective than Olmesartan. ICER was found to be 218.35.
Keywords
Olmesartan, Telmisartan, Cost Effectiveness, Hypertension, Angiotensin Receptor Blockers.- A Study of Anti-Hypertensive Drug Prescription Patterns in Hypertensive Post-Menopausal Women
Authors
1 Department of Pharmacology, Government Medical College, Patiala, Punjab, IN
2 Department of Medicine (Cardiology), Government Medical College, Patiala, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 7, No 1 (2018), Pagination: 1594-1603Abstract
Background: Drug prescription in menopause is complex as estrogen deficiency, hypertension (HT) and other risk factors, rapidly increase the risk of cardiovascular diseases (CVD) in post-menopausal women (PMW).
Objectives: To evaluate the prescription trends of anti-hypertensive drugs in PMW.
Methods: This was an observational, cross sectional study conducted over a period of 1 year, on hypertensive PMW. The prescriptions were evaluated for antihypertensive drug use patterns and also as per WHO core drug indicators.
Results: 21.82% of prescriptions had monotherapy, amongst which angiotensin receptor blockers (ARB) (10%) and individually, telmisartan (5.45%) were most commonly prescribed. Majority of prescriptions had two drug therapy (44.09%), among which ARB + beta-blockers (BB) (20.91%) and individually, Telmisartan + Metoprolol (13.64%) were most frequently prescribed. ARB + Diuretic (DI) (9.55%) was the most common fixed drug combination (FDC) prescribed. ARB + BB + DI (10.45%), ARB + 2DI + BB (4.09%) and ARB + 2DI + BB + Calcium channel blocker (1.82%) were most commonly prescribed three, four and ≥five drug combinations, respectively. Hypolipidemic drugs (60.45%) were maximally co-prescribed. Percentage of drugs prescribed by generic name was 4.63% and from essential drug list was 32.62%.
Conclusions: A high trend of polypharmacy was observed in hypertensive PMW. HT, being a multifactorial disease, deserves a multidisciplinary and a comprehensive approach in the care of this population subgroup. Knowledge of prescription pattern and thus the rational utilisation of drugs will help achieve better control rates of HT and hence curb down the burden of CVDs in PMW.
Keywords
Hypertension, Post-Menopausal Women, Prescription Pattern, Polypharmacy, Anti-Hypertensive Drugs.References
- Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001;32(5):1104-11.
- Howkins, Bourne. Shaw’s textbook of Gynaecology. 16th ed. Padubidri VG, Daftary SN, editors. India: Elsevier; 2015.p.65-78.
- Awotidebe TO, Adedoyin RA, Olola IL, Adeyeye VO, Akinola OT, Mbada CE, et al. Cardiovascular Risk Profile of Post-Menopausal Women in a Semi-Urban Community in Nigeria. Br J Med Med Res 2014;4(29):4780-90.
- Hanfy HM, Awad MA, Gharieb HO. Effect of Acupressure on Postmenopausal Hypertension. Bull Fac Ph Th Cairo Univ 2011;16(2):1-7.
- Robitaille NM. Hypertension in women. Can J Cardiol 1996;12 Suppl D:6D-8D.
- Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999–2004. Am J Hypertens 2008;21(7):789-98.
- Stamler R. Implications of the INTERSALT study. Hypertens 1991;17 Suppl 1:S16-20.
- Tandon VR, Sharma S, Mahajan S, Mahajan A, Khajuria V, Mahajan V, et al. Antihypertensive drug prescription patterns, rationality, and adherence to Joint National Committee-7 hypertension treatment guidelines among Indian postmenopausal women. J Mid-life Health 2014;5:78-83.
- Patta S. Drug Utilization Pattern of Antihypertensives in Geriatric and Non-Geriatric Population in a Tertiary Care Government Hospital Srikakulum, APJ Evol Med and Dent Sci 2015;4(13):2101-6.
- World Health Organization. Introduction to Drug Utilization Research [Internet]. Geneva: World Health Organization. 2003 – [Cited 2017 Sept]. Available from: http://apps.who.int/medicinedocs/pdf/s4876e/s4876e.pdf.
- National List of Essential Medicines 2015. [Internet]. India: National List of Essential Medicines. 2015 - [Cited 2017 Oct]. Available from: http://cdsco.nic.in/WriteReadData/NLEM2015/NLEM,%202015.pdf.
- Sharma AK, Dahiya N, Kairi JK, Bharati SM. Prescription patterns of antihypertensive drugs in a tertiary care hospital in India. Int J Basic Clin Pharmacol 2015;4(1):55-9.
- National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute (US). 2004 Aug - [Cited 2017 Aug 26]. Available from: https://www.nhlbi.nih.gov /files/docs/guidelines/jnc7full.pdf.
- Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr 2010;2(1):44.
- Panja M, Mondal S, Bhattacharya P, Mondal D. Beta Blocker in Combination with Other Antihypertensives. Supplement of JAPI 2009;57:35-7.
- Tiwari H, Kumar A, Kulkarni SK. Prescription monitoring of anti-hypertensive drug utilization at the Panjab University Health Centre in India. Singapore Med J 2004;45(3):117-20.
- Che Q, Schreiber MJ Jr, Rafey MA. Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med 2009;76(9):533-42.
- Sutters M. Systemic Hypertension. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current Medical Diagnosis & Treatment. 52nd ed. New York: McGraw Hill; 2013.p.433-63.
- Jeschke E, Ostermann T, Tabali M, Vollmar HC, Kröz M, Bockelbrink A, et al. Evaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study. BMC Fam Pract 2009;10:78-91.
- Skolnik NS, Beck JD, Clark M. Combination Antihypertensive Drugs: Recommendations for Use. Am Fam Physician 2000;61(10):3049-56.
- Cidda M, Mateti UV, Batchu MK, Martha S. Study of prescribing patterns of antihypertensives in South Indian population. Int J Basic Clin Pharmacol 2014;3(2):303-7.
- Sivakumar A, Venkateswaramurthy N, Sambathkumar R. Study of drug prescription pattern of anti-hypertensives in a tertiary care hospital. Der Pharmacia Lettre 2014;6(4):86-8.
- Beg MA, Dutta S, Varma A, Kant R, Bawa S, Anjoom M, et al. A study on drug prescribing pattern in hypertensive patients in a tertiary care teaching hospital at Dehradun, Uttarakhand. Int J Med Sci Public Health 2014;3(8):922-6.
- Tamuno I, Fadare J. Drug treatment for hypertension in a tertiary health care facility in northern Nigerian. Int J Pharm Biomed Res 2011;2(2):104-9.
- Comparative Study to Evaluate Efficacy, Safety and Quality of Life of Metoprolol and Telmisartan versus Metoprolol and Ramipril in Patients of Hypertension
Authors
1 Department of Pharmacology, Government Medical College, Patiala, Punjab - 147001, IN
2 Department of Medicine, Government Medical College, Patiala, Punjab - 147001, IN
Source
International Journal of Medical and Dental Sciences, Vol 8, No 2 (2019), Pagination: 1728-1738Abstract
Background: Hypertension(HTN) is a major cardiovascular disease and is a major worldwide clinical problem. The prevalence of hypertension increases in urban and rural areas. The treatment of hypertension began in the 1960s with oral diuretics. The other modalities of treatment of hypertension are beta – blockers, calcium-channel blockers, alphareceptors blockers, ACE inhibitors and ARBs. The better compliance occurs with single-pill combination, and may be even double or even triple pill combination therapy should be used. Also quality of life was improved better with Metoprolol and Telmisartan as compared with Metoprolol and Ramipril. Quality of life was assessed by SF -36 Quiestionnare. Objective: To compare the effect of Metoprolol and Telmisartan versus Metoprolol and Ramipril on BP and quality of life in patients of hypertension. Material and Methods: In this prospective, open, randomized, parallel group, comparative study, 80 patients of hypertension attending the Cardiology Outpatient Department, Govt. Medical College & Rajindra Hospital, Patiala were recruited. This randomized comparative study was done on 80 patients for 4 months. Quality of Life: In my project of Quality of life, I had taken total 80 patients and the patients were divided into two groups and 40 patients each of Metoprolol and Ramipril versus Metoprolol and Telmisartan. To assess quality of life questionnaire SF-36 was administered to the patients. Results: There was a marked decrease in SBP and DBP with the use of Metoprolol and Telmisartan than Metoprolol and Ramipril. There was also no change in demographic parameters. There was significant improvement in the quality of life with Metoprolol and Telmisartan. Conclusion: Metoprolol and Telmisartan was a better choice than Metoprolol and Ramipril in treating hypertension as this combination causes more reduction in BP and little effect on HR.
Keywords
DBP - Diastolic Blood Pressure, HR - Heart Rate, HRQOL - Health Related Quality of Life, HTN - Hypertension, SBP - Systolic Blood Pressure.References
- Benndorf RA, et al. Pleiotropic effects of telmisartan: Still more to come? J Hypertension. 2008; 26(5):854–6. https:// doi.org/10.1097/HJH.0b013e3282f76481 PMid:18398324
- Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008 Feb; 4(1):23–30. https://doi.org/10.2147/vhrm.2008.04.01.23 PMid:18629377 PMCid:PMC2464772
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC report. JAMA. 2003; 289(19):2560–72. https://doi.org/10.1001/jama.289.19.2560 PMid:12748199
- Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004 Feb; 18(2):73–8. https://doi.org/10.1038/sj.jhh.1001633 PMid:14730320
- Chrysant SG, Chyrysant GS, Dimas B. Current and future status of beta- blockers in the treatment of hypertension. Clinical Cardiology. 2008 Jun; 31(6):249–52. https://doi.org/10.1002/clc.20249 PMid:18543303
- Saseen JJ, MacLaughlin. Hypetension. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A pathophysiologic approach. 9th ed. New York: McGraw-Hill Medical; 2014.
- CDC: High blood pressure. Centers for Disease Control and Prevention; 2015. Available from: http://www.cdc.gov/bloodpressure/index.htm
- James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler K, Lackland DT, LeFevre M, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright J, Narva AS, Ortiz E. Evidence based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507–20. Available from: http://jama.jamanetwork.com/article.aspx?articleid=1791497 https://doi.org/10.1001/jama.2013.284427 PMid:24352797
- Friedrich MG, Dahlof B, Sechtem U, Unger T, Knecht M. Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as assessed by mabnetic resonance imaging in patients with mild-to-moderate hypertension- a prospective, randomized, double- blind comparison of telmisartan with metoprolol over a period of six months- rationale and study design. Journal of the Renin-Angiotensin-Aldosterone System. 2003 Dec; 4(4):234–43. https://doi.org/10.3317/jraas.2003.038 PMid:14689371
- Ong HT, FRCP, Rozina G, FRCP. Selecting antihypertensive medication in patients with essential hypertension in Malaysia. Med J Malaysia. 2009; 64(1):2009 Mar.
- Tomiyama H, Yamashina A. Beta- blockers in the management of hypertension and/or chronic kidney disease. International Journal of Hypertension. 2014; 1–7. https://doi.org/10.1155/2014/919256 PMid:24672712 PMCid:PMC3941231
- Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: Comparative effectiveness of angiotensin- converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008; 148:16–29. https:// doi.org/10.7326/0003-4819-148-1-200801010-00189 PMid:17984484
- Agarwal A, Chhabra MK, Walia R, Gupta PD. Comparative evaluation of Metoprolol and Telmisartan in hypertensive patients. 2014 Jul; 3(2): 403–10. Available from: www.Ijmds.org
- Kumar P, Kapoor AK, Singh HK, Kulshrestha M, Randomized. Interventional, prospective, comparative study to evaluate the antihypertensive efficacy and tolerability of Ramipril versus Telmisartan in stage 1 hypertensive patients with diabetes mellitus. Internet Journal of Medical Update. 2015 Jan; 10(1):15–25. https://doi.org/10.4314/ijmu.v10i1.4
- Zou Z, Xi G–L, Yuan HB, Zhu Q-F, Shi X-Y. Telmisartan versus Angiotensin converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. Journals of Human Hypertension. 2008; 23(5):1-11.
- Soni RK, Porter AC, Lash JP, Unruh ML. Health-related quality of life in hypertension, chronic kidney disease and coexistent chronic health conditions. Adv Chronic Kidney Dis. 2010 Jul; 17(4):e17–26. https://doi.org/10.1053/j.ackd.2010.04.002 PMid:20610351 PMCid:PMC2901238
- Shanableh S, Abdulkarem A, Shamssain M, Sarhan F. Quality of life of hypertensive patients on different types of antihypertensive medications. IOSR Journal of Pharmacy. 2014 May; 4(5):23–8. https://doi.org/10.9790/3013-0405023028